Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04258046 · ClinicalTrials.gov registry record · Phase 2
Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT04258046: Completed Phase 2 study, sponsored by Stanford University.
NCT04258046 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04258046, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Arteriovenous malformation (AVM) is a congenital vascular anomaly that progresses throughout life and causes complications including tissue destruction due to rapid overgrowth, bleeding, functional deficits, severe deformity and cardiac failure. Unfortunately, traditional managements have transient benefits with more than 90 recurrence rate within a year. Therefore, there is a significant unmet medical need. The purpose of this study is to assess the safety and efficacy of Trametinib in children and adults with Extracranial Arteriovenous Malformation (AVM).
Interventions
- DRUG Trametinib tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2026-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04258046
The ClinicalTrials.gov registry entry for NCT04258046 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trametinib tablet is the first listed.
NCT04258046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04258046 about?
NCT04258046 is a clinical study titled "Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation". Arteriovenous malformation (AVM) is a congenital vascular anomaly that progresses throughout life and causes complications including tissue destruction due to rapid overgrowth, bleeding, functional deficits, severe deformity and cardiac failure. Unfortunately, traditional managements have transient ...
What is the current status of trial NCT04258046?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2020-12-01. Estimated completion is 2026-02-18.
What interventions are being tested in trial NCT04258046?
The interventions under investigation include: Trametinib tablet (DRUG).
Who is sponsoring clinical trial NCT04258046?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.